Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Noting that the ultimate goal of PsA treatment is prompt reduction of ... bowel disease drives the occurrence of psoriasis or psoriatic arthritis—or whether the reverse is true.

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.